Updates in Use of ARIs and Ra-223 for Metastatic Castration-Resistant Prostate Cancer
An expert discusses the latest advancements in the use of androgen receptor inhibitors (ARIs) and radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer, highlighting their evolving roles in improving patient outcomes.
EP. 1: Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC
February 20th 2025An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after treatment with androgen receptor pathway inhibitors (ARPI) and docetaxel for localized prostate cancer.
Watch
EP. 2: Therapeutic options for a patient with mCRPC after ADT + docetaxel
February 20th 2025An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate cancer, such as abiraterone (ABI) based on COU-AA-301 and enzalutamide (ENZA) based on AFFIRM.
Watch
